Detailansicht

Wissensnetz

Person

Tibor Szarvas (1978-)

Arzt

Name	Tibor Szarvas
Zeit	1978- (Lebensdaten)
Ort	Ungarn
Beruf	Arzt (charakteristischer Beruf)
Variante	T. Szarvas
Beziehung	Universitätsklinikum Essen
Datensatztyp	Person
GND-Nummer	1017203822
Datensatz-ID	1017203822
Beteiligt an alle anzeigen Investigating the role of ultrasound-based shear wave elastography in kidney transplanted patients: correlation between non-invasive fibrosis detection, kidney dysfunction and biopsy results—a systematic review and meta-analysis Estimation of the incidence of urachal cancer: A systematic review and meta-analysis of registry-based studies Histopathological, molecular and clinical profiling of lymphoepithelioma-like carcinoma of the bladder (LELC-B) Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer Lifestyle-, environmental-, and additional health factors associated with an increased sperm DNA fragmentation: a systematic review and meta-analysis Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients—a systematic review and meta-analysis Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis Commentary: Treatment outcome of different chemotherapy in patients with relapsed or metastatic malignant urachal tumor Proteasomal processing immune escape mechanisms in platinum-treated advanced bladder cancer Correction to: COVID-19 research: promising tracks leading to uro-oncology Prevalence of APC and PTEN Alterations in Urachal Cancer Prevalence of APC and PTEN Alterations in Urachal Cancer Nuclear Localization of Robo is Associated with Better Survival in Bladder Cancer The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer Serum Chromogranin A as a Complementary Marker for the Prediction of Prostate Cancer-Specific Survival Validation of the diagnostic and prognostic relevance of serum MMP-7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Tibor Szarvas (1978-)

Investigating the role of ultrasound-based shear wave elastography in kidney transplanted patients: correlation between non-invasive fibrosis detection, kidney dysfunction and biopsy results—a systematic review and meta-analysis

Estimation of the incidence of urachal cancer: A systematic review and meta-analysis of registry-based studies

Histopathological, molecular and clinical profiling of lymphoepithelioma-like carcinoma of the bladder (LELC-B)

Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study

Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer

Lifestyle-, environmental-, and additional health factors associated with an increased sperm DNA fragmentation: a systematic review and meta-analysis

Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients—a systematic review and meta-analysis

Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis

Commentary: Treatment outcome of different chemotherapy in patients with relapsed or metastatic malignant urachal tumor

Proteasomal processing immune escape mechanisms in platinum-treated advanced bladder cancer

Correction to: COVID-19 research: promising tracks leading to uro-oncology

Prevalence of APC and PTEN Alterations in Urachal Cancer

Prevalence of APC and PTEN Alterations in Urachal Cancer

Nuclear Localization of Robo is Associated with Better Survival in Bladder Cancer

The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer

Serum Chromogranin A as a Complementary Marker for the Prediction of Prostate Cancer-Specific Survival

Validation of the diagnostic and prognostic relevance of serum MMP-7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method